Drug Guide
Spironolactone
Classification
Therapeutic: Diuretic, antihypertensive, aldosterone antagonist
Pharmacological: Aldosterone receptor antagonist, potassium-sparing diuretic
FDA Approved Indications
- Edematous conditions (e.g., heart failure, liver cirrhosis, nephrotic syndrome)
- Hypertension
- Primary hyperaldosteronism
- Acne vulgaris (off-label)
- Hormonal therapy for transgender women (off-label)
Mechanism of Action
Spironolactone competitively binds to aldosterone receptors in the distal convoluted tubules of the nephron, reducing sodium reabsorption and potassium excretion, leading to diuresis and decreased blood volume. It also has anti-androgen effects.
Dosage and Administration
Adult: Typically 25-200 mg daily in single or divided doses, adjusted based on clinical response.
Pediatric: Dosing based on weight and condition, usually starting at 2 mg/kg/day, up to a maximum of 4 mg/kg/day.
Geriatric: Start at lower doses due to increased susceptibility to side effects, monitor potassium and kidney function.
Renal Impairment: Use with caution; may require dose adjustments and close monitoring.
Hepatic Impairment: Use with caution; hepatic metabolism may be affected.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed in body tissues, crosses the placenta and enters breast milk.
Metabolism: Extensively metabolized in the liver to active and inactive metabolites.
Excretion: Eliminated mainly via urine and feces.
Half Life: Approximately 1.3 to 2 days (longer in patients with renal impairment).
Contraindications
- Hyperkalemia
- Anuria
- Significant renal impairment
- Addison's disease
Precautions
- Monitor serum potassium and renal function regularly.
- Use caution in patients with renal dysfunction, hepatic impairment, or concomitant use of other potassium-sparing agents.
Adverse Reactions - Common
- Hyperkalemia (Common)
- Gastrointestinal disturbances (nausea, vomiting, diarrhea) (Common)
- Dizziness, fatigue (Common)
Adverse Reactions - Serious
- Gynecomastia in men (Uncommon)
- Severe hyperkalemia leading to cardiac arrhythmias (Rare)
- Electrolyte imbalances (Rare)
Drug-Drug Interactions
- Potassium supplements, ACE inhibitors, ARBs, NSAIDs (may increase hyperkalemia risk)
- Other diuretics
Drug-Food Interactions
- Potassium-rich foods (monitor potassium levels)
Drug-Herb Interactions
N/ANursing Implications
Assessment: Monitor serum potassium, renal function, blood pressure, and fluid status.
Diagnoses:
- Risk for electrolyte imbalance
- Risk for dehydration
Implementation: Administer with food to reduce gastrointestinal upset. Educate patients about signs of hyperkalemia.
Evaluation: Assess for efficacy in controlling edema/hypertension and monitor adverse effects.
Patient/Family Teaching
- Instruct on the importance of regular blood tests to monitor potassium and kidney function.
- Advise to avoid potassium-rich foods and potassium supplements unless directed by healthcare provider.
- Report symptoms of hyperkalemia such as muscle weakness, irregular heartbeat.
Special Considerations
Black Box Warnings:
- Serious hyperkalemia may occur, especially in patients with renal impairment or with concomitant use of other hyperkalemia-inducing drugs.
Genetic Factors: Consider pharmacogenomics for androgen-related side effects.
Lab Test Interference: May cause false rise in serum testosterone measurement.
Overdose Management
Signs/Symptoms: Hyperkalemia, dizziness, hypotension, dehydration.
Treatment: Discontinue medication, administer calcium gluconate for cardiac stabilization if needed, initiate potassium-lowering therapies, initiate IV fluids, and monitor ECG.
Storage and Handling
Storage: Store at room temperature away from moisture and heat.
Stability: Stable under recommended storage conditions.